Long-Term Results of Melphalan-Based Isolated Limb Perfusion With or Without Low-Dose TNF for In-Transit Melanoma Metastases
- 29 April 2010
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 17 (11) , 3000-3007
Abstract
Background The aims of the study were: (1) to determine toxicity, response rate, local-regional control, and survival in the entire population of the perfused patients; (2) to compare toxicity,...Keywords
This publication has 26 references indexed in Scilit:
- Analysis of Factors Influencing Outcome in Patients With In-Transit Malignant Melanoma Undergoing Isolated Limb Perfusion Using Modern Treatment ParametersJournal of Clinical Oncology, 2010
- Hyperthermic Isolated Limb Perfusion With Tumor Necrosis Factor Is a Useful Therapy for Advanced Melanoma of the LimbsJournal of Clinical Oncology, 2007
- Long-term Results of Hyperthermic, Isolated Limb Perfusion for MelanomaAnnals of Surgery, 2007
- TNF dose reduction in isolated limb perfusionEuropean Journal of Surgical Oncology, 2005
- One Hundred Consecutive Isolated Limb Perfusions With TNF-α and Melphalan in Melanoma Patients With Multiple In-Transit MetastasesAnnals of Surgery, 2004
- Factors Affecting Survival After Complete Response to Isolated Limb Perfusion in Patients With In-Transit MelanomaAnnals of Surgical Oncology, 2001
- Regional toxicity after isolated limb perfusion with melphalan and tumour necrosis factor- α versus toxicity after melphalan aloneEuropean Journal of Surgical Oncology, 2001
- Relation between limb toxicity and treatment outcomes after isolated limb perfusion for recurrent melanomaJournal of the American College of Surgeons, 1999
- Thirty-five years of isolated limb perfusion for melanoma: Indications and resultsBritish Journal of Surgery, 1996
- Dosimetry in isolation perfusion of the limbs by assessment of perfused tissue volume and grading of toxic tissue reactionsEuropean Journal of Cancer and Clinical Oncology, 1982